Trovagene expands the use of Onvansertib
Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.
Read more
Xtandi
Pfizer/Astellas’s cancer drug study fails
Pfizer and Astellas Pharma have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with
Read more
Astellas’s and Pfizer’s cancer drug gets new product label data
Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …
Read more